Has Monica Martin received payments from drug or device companies?

Yes. Drug and device makers reported $1,516 in general payments to Monica Martin across 68 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Monica Martin did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Monica Martin come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Monica Martin

Family · Pensacola, FLNPI 1972191831

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 68 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,293 and has fallen 88.9% since, to $144 in 2023.

$1,516in general payments, 2019–2025

Across 68 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AstraZeneca$345
Novo Nordisk$175
Esperion Therapeutics, Inc.$133
Lilly USA, LLC$108
Pfizer$106
GSK$98
plus $551 from 17 others

What the payments were for

Food & beverage$1,516100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AstraZeneca	10	$345
Novo Nordisk	7	$175
Esperion Therapeutics, Inc.	2	$133
Lilly USA, LLC	3	$108
Pfizer	6	$106
GSK	6	$98
Boehringer Ingelheim	5	$90
Johnson & Johnson	5	$71
Astellas Pharma US Inc	4	$59
Merck	3	$43
Takeda Pharmaceuticals U.S.A., Inc.	2	$40
Amarin Pharma, Inc.	2	$35
Adlon Therapeutics L.p.	2	$33
Sunovion Pharmaceuticals Inc.	2	$29
Corcept Therapeutics	1	$24
Ironwood Pharmaceuticals, Inc	1	$19
Bayer	1	$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$18
Biohaven Pharmaceuticals, Inc.	1	$16
Medline Industries LP	1	$16
Supernus Pharmaceuticals, Inc.	1	$15
Otsuka America Pharmaceutical, Inc.	1	$13
Kowa Pharmaceuticals America, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,516 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.

See all family providers in Florida →

Other family in Pensacola

Brittany PerezPensacola$130K
Mary AanestadPensacola$54K
Raymond HalsteadPensacola$50K
Lewis HarringtonTampa$954K
Danielle PharesFt Lauderdale$713K
Donna OrtizOrlando$417K
Patrick SzarazMiami$327K
Deena RodneyMaitland$323K
Yamila MelendezMiami$212K
Holly BoydLand O Lakes$200K

See the full list for Florida →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →